Sicart Associates LLC Sells 3,579 Shares of Illumina, Inc. $ILMN

Key Points

• Sicart Associates LLC reduced its stake in Illumina, Inc. by 5.9% during Q2, now holding 57,005 shares worth approximately $5.44 million.
• Analysts have recently adjusted ratings and price targets on Illumina, ranging from $90.00 to $125.00, with a consensus average price target of $123.06.
• Illumina reported Q2 earnings of $1.19 per share, outperforming expectations, but saw a 4.8% decrease in revenue year-over-year.

Sicart Associates LLC trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,005 shares of the life sciences company's stock after selling 3,579 shares during the quarter. Illumina makes up about 1.9% of Sicart Associates LLC's investment portfolio, making the stock its 21st biggest position. Sicart Associates LLC's holdings in Illumina were worth $5,439,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ILMN. Corvex Management LP grew its stake in Illumina by 125.2% during the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company's stock worth $303,841,000 after buying an additional 2,129,449 shares during the last quarter. AQR Capital Management LLC grew its stake in Illumina by 361.7% during the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company's stock worth $165,484,000 after buying an additional 1,662,093 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Illumina by 11,714.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company's stock worth $92,184,000 after buying an additional 1,152,048 shares during the last quarter. Brown Advisory Inc. grew its stake in Illumina by 52.1% during the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock worth $230,818,000 after buying an additional 996,589 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Illumina by 2,057.5% during the first quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock worth $73,174,000 after buying an additional 879,533 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Daiwa Capital Markets cut shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective on the stock. in a research note on Tuesday, August 12th. Scotiabank cut shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective on the stock. in a research note on Friday, July 11th. Barclays increased their price target on shares of Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a research note on Friday, August 1st. Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a research note on Tuesday, September 2nd. Finally, Wall Street Zen cut shares of Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Six investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Illumina currently has an average rating of "Hold" and a consensus price target of $123.06.

Illumina Price Performance

Shares of ILMN stock opened at $94.97 on Wednesday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The stock has a market cap of $14.60 billion, a PE ratio of 12.02, a PEG ratio of 2.22 and a beta of 1.43. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The firm's 50 day moving average price is $99.42 and its two-hundred day moving average price is $89.55.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same period last year, the firm earned $0.36 earnings per share. The business's revenue for the quarter was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.